Articles: ninos.
-
Un enfant de 2 ans est récemment venu à ma clinique en raison d'épisodes répétés de raidissements du cou et de mouvements de frissons aux épaules et aux bras. Les épisodes durent de 4 à 5 secondes et se produisent plus de 10 fois par jour, sans modèle apparent, outre une fréquence accrue à l'heure des repas. Même s'il n'a pas eu de perte de conscience, les parents s'inquiétaient qu'il ait des convulsions. ⋯ Des constatations normales à un examen neurologique et au tracé d'un électroencéphalogramme confirmeront que l'enfant a des accès de frissonnement, un phénomène bénin qui ne requiert pas d'examen plus approfondi ou de traitement médical. La cause de cet état est inconnue, mais il se distingue de l'épilepsie et ne nécessite pas de médicaments antiépileptiques, auxquels il ne répond pas. Les parents peuvent avoir l'assurance que les accès diminueront en fréquence et disparaîtront spontanément avec l'âge.
-
[This corrects the article DOI: 10.1371/journal.pmed.1003402.].
-
Recent research in atopic dermatitis (AD) has identified it to be a heterogeneous inflammatory skin disorder of different endotypes (immune polarisation of T-cell subsets and genetic mutations) underlying various phenotypes (age of onset, ethnicity, disease severity, etc.). The corresponding heterogeneity in underlying patho-mechanisms of the disease has resulted in an impetus towards an endotype-driven management of AD. We propose a practical approach that is based on classifying AD patients into intrinsic and extrinsic phenotypes and their corresponding underlying endotypes. This approach aims to provide a practical method that integrates recent understanding of AD pathogenesis for a targeted endotype-driven management of AD.
-
J Coll Physicians Surg Pak · Feb 2021
Meta AnalysisEfficacy of Standardised Treatments Combined with Ubenimex in Patients with Malignant Tumors.
Ubenimex is widely used as an immunomodulator in the treatment of leukemia and non-small cell lung cancer to improve the anti-tumor treatment effect. However, there has not been any multicenter randomised controlled trials to study its impact on the prognosis of cancer patients. The authors aimed to conduct a meta-analysis to initially study these issues. ⋯ Between the ubenimex group and the control group, the 1-year OR was 1.40 (95% CI = 1.06 to 1.85), the 2-year OR was 1.43 (95% CI = 1.08 to 1.89) and the 3-year OR was 1.39 (95% CI = 1.07 to 1.81). Standardised treatments combined with ubenimex may improve the survival rate of patients with malignant tumors. Key Words: Malignant tumors, Ubenimex, Randomised controlled trials, Meta-analysis.
-
J Coll Physicians Surg Pak · Feb 2021
Randomized Controlled Trial Observational StudyImpact of Intraoperative Dexmedetomidine versus Remifentanil on Recovery Characteristics following Laparoscopic Sleeve Gastrectomy.
To evaluate the impact of intraoperative dexmedetomidine versus remifentanil on postoperative pain; and enhanced recovery profile in patients scheduled for laparoscopic sleeve gastrectomy (LSG). ⋯ Better enhanced recovery profile after LSG supports the use of intraoperative infusion of dexmedetomidine as an anaesthetic adjuvant versus remifentanil. Key Words: Dexmedetomidine, Remifentanil, Enhanced recovery after surgery (ERAS); Bariatric surgery.